Inclusive of all taxes
ITRASPORAX 50 SB CAP is a high-quality, sustained-release antifungal capsule containing 50 mg of Itraconazole, formulated for extended and consistent plasma concentrations to combat both superficial and systemic fungal infections effectively. Manufactured by BluepillExpress under the Dr Precision label, this product adheres to GMP standards ensuring premium quality and precision. Its unique sustained-release formulation ensures a gradual and prolonged delivery of Itraconazole, improving bioavailability and patient adherence. With a broad-spectrum efficacy against dermatophytes, yeasts, and systemic fungi, ITRASPORAX 50 SB CAP is ideal for treating various fungal conditions including Dermatophytosis, Onychomycosis, Pityriasis versicolor, candidiasis (oral, esophageal, vaginal), Aspergillosis, Histoplasmosis, Blastomycosis, Sporotrichosis, and resistant fungal infections. Its superior lipophilic tissue penetration sets it apart from other antifungals, enabling treatment of deep tissue and systemic infections. Recommended dosages vary by condition and should be taken with food to enhance absorption, with adjustments for hepatic impairment as necessary.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Itraconazole 50 mg |
| Formulation | Sustained-Release Capsule (SB) |
| Spectrum | Broad-spectrum antifungal activity against dermatophytes, yeasts, and systemic fungi |
| Indications | Dermatophytosis, Onychomycosis, Pityriasis versicolor, Candidiasis (oral, esophageal, vaginal), Aspergillosis, Histoplasmosis, Blastomycosis, Sporotrichosis |
| Mechanism of Action | Inhibits fungal lanosterol 14-alpha-demethylase to disrupt ergosterol synthesis |
| Bioavailability Enhancement | Sustained release improves bioavailability and ensures prolonged plasma concentration |
| Patient Compliance | Lower dosage frequency improves adherence |
| Tissue Penetration | Superior lipophilic tissue penetration |
| Manufacturer | BluepillExpress (Global third-party manufacturer) |
| Quality Assurance | GMP compliant, Dr Precision label |
| Attributes | Description |
|---|---|
| Dosage Form | Oral Capsule |
| Strength | 50 mg Itraconazole per capsule |
| Release Type | Sustained-Release (SB) |
| Storage | Store in a cool, dry place away from direct sunlight |
| Shelf Life | As per manufacturer guidelines |
| Recommended Dosage | 50–200 mg/day, varies by fungal infection type |
| Administration Instructions | Take with food for improved absorption |
| Hepatic Adjustment | Dosage adjustments required in hepatic impairment |
| Therapeutic Class | Triazole Antifungal |
| Packaging | Capsules per blister/strip as per packaging norms |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
The sustained-release formulation ensures gradual and prolonged delivery of Itraconazole, maintaining consistent plasma levels which improve antifungal efficacy, extend therapeutic activity, enhance bioavailability, and reduce the frequency of doses required, leading to better patient compliance.
Yes, due to its superior lipophilic tissue penetration and broad-spectrum antifungal activity, ITRASPORAX 50 SB CAP is effective for systemic fungal infections such as Aspergillosis, Histoplasmosis, Blastomycosis, and Sporotrichosis.
ITRASPORAX 50 SB CAP should be taken with food as the bioavailability of Itraconazole is significantly enhanced when consumed along with meals.
Yes, since Itraconazole is metabolized in the liver, patients with hepatic impairment require dosage adjustments to avoid toxicity and ensure therapeutic safety.
Compared to other azoles, ITRASPORAX provides prolonged sustained-release delivery, superior lipophilic tissue penetration for systemic infections, improved bioavailability, and reduced dosing frequency, which collectively enhance efficacy and patient adherence.
Yes, ITRASPORAX contains Itraconazole, which is effective against several fungal strains that often develop resistance to fluconazole, making it a preferred alternative.
Country Of Origin: India
ITRASPORAX 50 SB CAP contains Itraconazole 50 mg in a sustained-release formulation, designed to provide extended antifungal action with consistent plasma concentration. It is highly effective in treating superficial and systemic fungal infections. Manufactured by BluepillExpress, a global third-party pharmaceutical leader, ITRASPORAX ensures world-class quality, patient compliance, and trusted therapeutic results.
This product is manufactured under the Dr Precision label, ensuring GMP-compliant quality and precision formulation standards.
ITRASPORAX 50 SB CAP is a broad-spectrum antifungal formulation containing Itraconazole 50 mg, a potent triazole derivative with high efficacy against dermatophytes, yeasts, and systemic fungi. This sustained-release (SB) form is developed to deliver a gradual release of Itraconazole, ensuring longer-lasting therapeutic activity, improved bioavailability, and better patient adherence.
Itraconazole acts by inhibiting the fungal cytochrome P450-dependent enzyme lanosterol 14-alpha-demethylase, a critical enzyme in the synthesis of ergosterol, an essential component of fungal cell membranes. By disrupting this pathway, Itraconazole halts fungal cell growth and replication.
Indications and Therapeutic Uses
ITRASPORAX 50 SB CAP is recommended in the treatment of:
Dermatophytosis (Tinea corporis, Tinea cruris, Tinea pedis)
Onychomycosis (fungal nail infections)
Pityriasis versicolor
Oral and esophageal candidiasis
Vaginal candidiasis
Aspergillosis (non-invasive)
Histoplasmosis & Blastomycosis
Sporotrichosis and systemic mycoses
Fungal infections resistant to fluconazole
Key Benefits of ITRASPORAX 50 SB CAP
Sustained release ensures prolonged antifungal effect
Effective in both superficial and deep/systemic fungal infections
Superior to other azoles in lipophilic tissue penetration
Lower dosage frequency enhances patient compliance
Bioavailability improved when taken with food
Suitable for long-term antifungal therapy
Dosage and Administration
Usual adult dosage: 50–200 mg/day, depending on indication
Fungal skin infections: 50–100 mg once or twice daily for 2–4 weeks
Onychomycosis: Pulse therapy 200 mg twice daily for 1 week/month over 3–4 months
Should be taken with food to enhance absorption
Dosage adjustments required in hepatic impairment
Note: Always follow physician's recommendations for duration and dosage.
Inclusive of all taxes
You Save: 0
Surat , India
Manufacturer, Contractor, Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24abdfb4194j1ze
